Clinically Proven Effectiveness of Our Hyaluronic Acid-Based Vaginal Medical Device for Women’s Intimate Health Gruppo FarmaImpresa is proud to share the results of its clinical study, conducted on the medical device Revaginal Ovules. The study evaluated the safety and effectiveness of our vaginal ovules in promoting vaginal and uterine tissue regeneration, offering an innovative and…
MDD Certified Vaginal Tablets for Intimate Health The Medical Device Regulation (MDR), in effect since May 2017 and fully applicable from May 2021, regulates medical devices in Europe. Thanks to deadline extensions, devices compliant with the MDD Directive can continue to be marketed until December 31, 2027, for Class III and implantable Class IIb devices,…
MDD Certification for Our Vaginal Ovules: A New Milestone for Intimate Health The MDR Regulation, in force since May 2017 and applicable from May 2021, governs European medical devices. Deadline extensions allow medical devices compliant with the Medical Device Directive (MDD) to be marketed until December 31, 2027, for Class III and implantable Class IIb…
Treatment for Vulvovaginal Mycotic Infections: FarmaImpresa Group certifies a new Medical Device in Macedonia We have completed the registration with the competent authorities in Macedonia for a Class I medical device, designed for the treatment of vulvovaginal mycotic infections. The medical device is formulated as a vaginal suppository based on hyaluronic acid, boric acid, and…